Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors.

Autor: Wémeau JL; Service endocrinologie diabétologie métabolismes, CHRU de Lille, hôpital Claude-Huriez, 59000 Lille, France., Klein M; Service endocrinologie, CHU de Nancy, hôpital de Brabois, Vandoeuvre-lès-Nancy, France., Sadoul JL; Service endocrinologie, CHU de Nice, hôpital de l'Archet, 06202 Nice, France., Briet C; Service endocrinologie-diabétologie-nutrition, CHU d'Angers, France., Vélayoudom-Céphise FL; Service d'endocrinologie-diabétologie-nutrition, CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, France. Electronic address: fritz-line.cephise@chu-guadeloupe.fr.
Jazyk: angličtina
Zdroj: Annales d'endocrinologie [Ann Endocrinol (Paris)] 2018 Dec; Vol. 79 (6), pp. 599-607. Date of Electronic Publication: 2018 Sep 11.
DOI: 10.1016/j.ando.2018.09.002
Abstrakt: Graves' disease is the most frequent cause of hyperthyroidism. Many questions remain about the choice of diagnostic evaluations and treatment strategy according to clinical context (age, gender, pregnancy, etc.) and about the best management of the main extrathyroidal complication that is Graves orbitopathy. The exact pathogenic mechanisms are not fully clear. They associate genetic factors, interactions between endogenous and environmental factors, and immune system dysregulation. Graves' orbitopathy is one of the consequences of this partial understanding. Iatrogenic Graves' disease induced by the new targeted therapies are described and could help to better understand the molecular pathways involved in the disease and to develop new therapeutic approaches.
(Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: